has been cited by the following article(s):
|
[1]
|
The Impact of ABCB1 SNPs on Tacrolimus Pharmacokinetics in Liver or Kidney
Transplant Recipients: A Meta-analysis
Current Pharmaceutical Design,
2023
DOI:10.2174/0113816128259239231009112019
|
|
|
|
|
[2]
|
Clinical significance of personalized tacrolimus dosing by adjusting to donor CYP3A‐status in liver transplant recipients
British Journal of Clinical Pharmacology,
2021
DOI:10.1111/bcp.14566
|
|
|
|
|
[3]
|
Recipient ABCB1, donor and recipient CYP3A5 genotypes influence tacrolimus pharmacokinetics in liver transplant cases
Pharmacological Reports,
2019
DOI:10.1016/j.pharep.2019.01.006
|
|
|
|
|
[4]
|
Effect of CYP3A5*1 expression on tacrolimus required dose after liver transplantation: A systematic review and meta‐analysis
Clinical Transplantation,
2018
DOI:10.1111/ctr.13306
|
|
|
|
|
[5]
|
Effect of CYP3A5*1 expression on tacrolimus required dose after liver transplantation: A systematic review and meta-analysis
Clinical Transplantation,
2018
DOI:10.1111/ctr.13306
|
|
|
|
|
[6]
|
Effect of ABCB1 (3435C>T) and CYP3A5 (6986A>G) genes polymorphism on tacrolimus concentrations and dosage requirements in liver transplant patients
Egyptian Journal of Medical Human Genetics,
2017
DOI:10.1016/j.ejmhg.2016.10.005
|
|
|
|